Search results for " ALPHA"

showing 10 items of 1610 documents

Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis

2007

Abstract The transcription factor STAT4 mediates signals of various proinflammatory cytokines, such as IL-12, IL-15, and IL-23, that initiate and stabilize Th1 cytokine production. Although Th1 cytokine production has been suggested to play a major pathogenic role in rheumatoid arthritis, the role of STAT4 in this disease is poorly understood. In this study, we demonstrate a key functional role of STAT4 in murine collagen-induced arthritis (CIA). In initial studies we found that STAT4 expression is strongly induced in CD4+ T cells and to a lesser extent in CD11b+ APCs during CIA. To analyze the role of STAT4 for arthritis manifestation, we next investigated the outcome of interfering with S…

musculoskeletal diseasesImmunologyAntigen-Presenting CellsCodon InitiatorArthritisBiologyProinflammatory cytokineArthritis RheumatoidPathogenesisMiceimmune system diseasesmedicineAnimalsImmunology and Allergyskin and connective tissue diseasesSTAT4Cells CulturedMice KnockoutMice Inbred BALB CCD11b Antigenhemic and immune systemsOligonucleotides AntisenseSTAT4 Transcription FactorTh1 CellsThionucleotidesmedicine.diseaseArthritis ExperimentalIntegrin alpha MRheumatoid arthritisImmunologybiology.proteinExperimental pathologyTumor necrosis factor alpha
researchProduct

Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

2014

Abstract Tumor necrosis factor alpha (TNF-?) is an important pro-inflammatory cytokine associated with a variety of ocular diseases. The currently available TNF-? inhibitors are etanercept, infliximab, adalimumab, golimumab, and certolizumab. Experimental and clinical studies on the intravitreal use of these agents have been reported with etanercept, infliximab, and adalimumab: etanercept has shown limited efficacy in scarce reports; infliximab has been associated with local safety concerns but appears to benefit certain cases; adalimumab has shown no efficacy in cases of age-related macular degeneration (AMD) or diabetic macular edema (DME), but the combination with bevacizumab may be effe…

musculoskeletal diseasesOncologymedicine.medical_specialtyPathologygenetic structuresBevacizumabReviewCertolizumabEtanerceptEtanerceptIntravitreal injectionInternal medicineOcular disordersmedicineAdalimumabskin and connective tissue diseasesTumor necrosis factor alphabusiness.industryAdalimumabMacular degenerationmedicine.diseaseInfliximabeye diseasesGolimumabInfliximabOphthalmologyInfectious DiseasesTumor necrosis factor alphasense organsbusinessmedicine.drugJournal of Ophthalmic Inflammation and Infection
researchProduct

COL1A1 Sp1 polymorphism associates with bone density in early puberty.

2006

Optimal acquisition of bone mass in puberty is a key determinant of the lifetime risk of osteoporosis and has a strong genetic basis. We investigated the relationship between the COL1A1 Sp1 polymorphism and BMD in early puberty, and how the genotypes relate to bone size and geometry as well as bone turnover and material properties in 247 10- to 13-year-old girls. Bone properties were measured using DXA, pQCT, and ultrasound. Also, serum P1NP, OC, B-ALP, and TRACP 5b were assessed. Our results showed that girls with the TT genotype had significantly lower BMC and BMD of the total body, lumbar spine, and proximal femur, as well as BUA at the calcaneus, than those with the GT and GG genotype. …

musculoskeletal diseasesPeak bone massmedicine.medical_specialtyHistologyTime FactorsBone densityAdolescentGenotypePhysiologyEndocrinology Diabetes and MetabolismOsteoporosisPuberty PrecociousCollagen Type IBone remodelingBone DensityInternal medicineGenotypeMedicineHumansChildPolymorphism GeneticProximal femurbusiness.industrymusculoskeletal systemmedicine.diseaseCollagen Type I alpha 1 ChainEndocrinologyFemaleCalcaneusbusinessBiomarkersEarly pubertyBone
researchProduct

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

2020

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drugPediatric Dermatology
researchProduct

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…

musculoskeletal diseasesmedicine.medical_treatmentImmunologyAnti-Inflammatory AgentsDrug Evaluation PreclinicalType II collagenArthritisInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyMiceRheumatologyOrganometallic CompoundsPerception and Action [DCN 1]medicineAnimalsImmunology and AllergyChronic inflammation and autoimmunity [UMCN 4.2]Dose-Response Relationship Drugbiologybusiness.industryRANK LigandInterleukinIntercellular Adhesion Molecule-1medicine.diseaseArthritis ExperimentalPathogenesis and modulation of inflammation [N4i 1]Cellular infiltrationCyclooxygenase 2Mice Inbred DBARANKLImmunologybiology.proteinCytokinesTumor necrosis factor alphaMicrobial pathogenesis and host defense [UMCN 4.1]Inflammation Mediatorsmedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1Immunity infection and tissue repair [NCMLS 1]Prostaglandin E
researchProduct

A new species of Rhopalosiphum (Hemiptera, Aphididae) on Chusquea tomentosa (Poaceae, Bambusoideae) from Costa Rica

2012

copyright 2012, Los autores y Zookeys. Datos incluidos por Lisela Moreira Carmona, responsable de depósitos del área de Patógenos y Plagas de Plantas (CIBCM-UCR). The new species Rhopalosiphum chusqueae Pérez Hidalgo & Villalobos Muller, is described from apterous viviparous females caught on Chusquea tomentosa in Cerro de la Muerte (Costa Rica). The identity of the species is supported both by the morphological features and by a molecular phylogenetic analysis based on a fragment of the mitochondrial DNA containing the 5’ region of the cytochrome c oxidase 1 (COI) and on the nuclear gene coding for the Elongation factor-1 alpha (EF1α). The taxonomic position of the new species is discussed…

new speciesCosta RicaRhopalosiphumbiologyAphididae539.752 728 6 Homopterabiology.organism_classificationBambusoideaeRhopalosiphumHemipteraArticleaphidsBotanylcsh:ZoologyRhopalosiphum chusqueaeElongation factor-1 alphaAnimal Science and ZoologyPoaceaeChusquea tomentosaTaxonomy (biology)molecularlcsh:QL1-991Ecology Evolution Behavior and SystematicsCytochrome c oxidase 1ZooKeys
researchProduct

Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of RORa in adipose tissue inflammation associated to obesity

2021

El aneurisma aórtico abdominal (AAA) se define como una dilatación local de la arteria aorta a nivel abdominal cuya consecuencia más grave es su ruptura si no se detiene su crecimiento y progresión. Los rasgos patológicos del AAA incluyen un estado inflamatorio crónico que afecta a la pared vascular de la aorta, una degradación progresiva de la matriz extracelular y un aumento en la neovascularización. Esta enfermedad presenta una elevada tasa de mortalidad y en la actualidad el único tratamiento efectivo que se conoce es la intervención quirúrgica, pero no está indicada en pacientes asintomáticos o que presentan un aneurisma de reducido tamaño. Por ello, es fundamental encontrar nuevas est…

obesityabdominal aortic aneurysminflammationSGLT-2 inhibitorsUNESCO::CIENCIAS MÉDICASangiotensin II:CIENCIAS MÉDICAS [UNESCO]retinoic acid receptor-related orphan receptor alphaadipose tissue dysfunction
researchProduct

A novel intrinsically disordered outer membrane lipoprotein ofAggregatibacter actinomycetemcomitansbinds various cytokines and plays a role in biofil…

2017

Intrinsically disordered proteins (IDPs) do not have a well-defined and stable 3-dimensional fold. Some IDPs can function as either transient or permanent binders of other proteins and may interact with an array of ligands by adopting different conformations. A novel outer membrane lipoprotein, bacterial interleukin receptor I (BilRI) of the opportunistic oral pathogen Aggregatibacter actinomycetemcomitans binds a key gatekeeper proinflammatory cytokine interleukin (IL)-1b. Because the amino acid sequence of the novel lipoprotein resembles that of fibrinogen binder A of Haemophilus ducreyi, BilRI could have the potential to bind other proteins, such as host matrix proteins. However, from th…

outer membrane lipoproteinsbacterial cytokine receptorbiofilm matrix composition0301 basic medicineMicrobiology (medical)Virulence FactorsLipoproteinsInterleukin-1beta030106 microbiologyImmunologyGingivaBiologyIntrinsically disordered proteinsAggregatibacter actinomycetemcomitansMicrobiologybacterial cytokine receptors03 medical and health sciencesHumansInterleukin 8Periodontal Diseasesouter membrane lipoproteinTumor Necrosis Factor-alphaInterleukin-8ta1182Biochemistry and Molecular BiologyBiofilmAggregatibacter actinomycetemcomitansReceptors Interleukin-1food and beveragesintrinsically disordered proteinbiology.organism_classificationInterleukin-10Cell biologyIntrinsically Disordered ProteinsInterleukin 10EditorialInfectious DiseasesBiochemistryBiofilmsParasitologyTumor necrosis factor alphabiofilm matrix compositionsintrinsically disordered proteinsBacterial outer membraneBiokemi och molekylärbiologiResearch PaperBacterial Outer Membrane ProteinsLipoproteinVirulence
researchProduct

Oxymetazoline modulates proinflammatory cytokines and the T‐cell stimulatory capacity of dendritic cells

2007

The nasal decongestant oxymetazoline (OMZ) is frequently used in the topical treatment of rhinitis/sinusitis. As proinflammatory cytokines play a critical role in the development and maintenance of local inflammation, the aim of this study was to investigate the influence of OMZ on immune cells in order to diminish the mucosal infiltration of the nose. Peripheral blood mononuclear cells (PBMC) from buffy coats of healthy volunteers were isolated and stimulated in the presence or absence of OMZ. In addition, monocyte-derived dendritic cells (DC) were generated and different concentrations of OMZ were added. DC phenotype and their T-cell stimulatory properties were analysed. The vasoactive su…

oxymetazolinemedicine.medical_treatmentT cellT-LymphocytesInflammationEnzyme-Linked Immunosorbent AssayDermatologyimmunomodulationLymphocyte ActivationBiochemistryProinflammatory cytokinerhinitismedicineHumansAntigen-presenting cellMolecular BiologyCells CulturedDose-Response Relationship Drugbusiness.industryImmunomagnetic SeparationDendritic cellDendritic CellsFlow CytometryNasal decongestantNasal DecongestantsCytokinemedicine.anatomical_structureImmunologyproinflammatory cytokinesLeukocytes MononuclearCytokinesTumor necrosis factor alphaOriginal Articlemedicine.symptombusinessExperimental Dermatology
researchProduct

Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS.

2005

Phosphorylated p38 mitogen-activated protein kinase (p38MAPK), but not activated c-jun-N-terminal kinase (JNK), increases in the motor neurons of transgenic mice overexpressing ALS-linked SOD1 mutants at different stages of the disease. This effect is associated with a selective increase of phosphorylated MKK3-6, MKK4 and ASK1 and a concomitant upregulation of the TNFalpha receptors (TNFR1 and TNFR2), but not IL1beta and Fas receptors. Activation of both p38 MAPK and JNK occurs in the activated microglial cells of SOD1 mutant mice at the advanced stage of the disease; however, this effect is not accompanied by the concomitant activation of the upstream kinases ASK1 and MKK3,4,6, while both …

p38 mitogen-activated protein kinasesMAP Kinase Kinase 3Mice TransgenicMAP Kinase Kinase 6BiologyMAP Kinase Kinase Kinase 5p38 Mitogen-Activated Protein KinasesReceptors Tumor Necrosis FactorCellular and Molecular NeuroscienceMiceSuperoxide Dismutase-1Downregulation and upregulationAnimalsHumansASK1RNA Messengerfas ReceptorPhosphorylationReceptorProtein kinase AMolecular BiologyP38MAPK cascadeMotor NeuronsKinaseSuperoxide DismutaseTumor Necrosis Factor-alphaAmyotrophic Lateral SclerosisJNK Mitogen-Activated Protein KinasesReceptors Interleukin-1Cell BiologyCell biologyEnzyme ActivationMice Inbred C57BLDisease Models AnimalTumor Necrosis Factor Decoy ReceptorsSpinal CordReceptors Tumor Necrosis Factor Type IDisease ProgressionTumor necrosis factor alphaSignal TransductionMolecular and cellular neurosciences
researchProduct